Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term Bladder cancer. Found 21 abstracts

no pagination
Bandini M, Briganti A, Plimack ER, Niegisch G, Yu EY, Bamias A, Agarwal N, Sridhar SS, Sternberg CN, Vaishampayan U, Theodore C, Rosenberg JE, Bellmunt J, Galsky MD, Montorsi F, Necchi A. Modeling 1-year Relapse-free Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients with Clinical T2-4N0M0 Urothelial Bladder Carcinoma: Endpoints for Phase 2 Trials. European urology oncology. 2019 May;2(3):248-56.
Necchi A, Pond GR, Moschini M, Plimack ER, Niegisch G, Yu EY, Bamias A, Agarwal N, Vaishampayan U, Theodore C, Sridhar SS, Rosenberg JE, Bellmunt J, Gallina A, Colombo R, Montorsi F, Briganti A, Galsky MD. Development of a Prediction Tool for Exclusive Locoregional Recurrence After Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer. Clin Genitourin Cancer. 2019 Feb;17(1):7-14e3.
Wang L, Gong Y, Saci A, Szabo PM, Martini A, Necchi A, Siefker-Radtke A, Pal S, Plimack ER, Sfakianos JP, Bhardwaj N, Horowitz A, Farkas AM, Mulholland D, Fischer BS, Oh WK, Sharma P, Zhu J, Galsky MD. Fibroblast Growth Factor Receptor 3 Alterations and Response to PD-1/PD-L1 Blockade in Patients with Metastatic Urothelial Cancer. Eur Urol. 2019 Nov;76(5):599-603.   PMCID: PMC6801024
Godwin JL, Hoffman-Censits J, Plimack E. Recent developments in the treatment of advanced bladder cancer. Urol Oncol. 2018 Mar;36(3):109-14.   PMCID: Review
Hahn NM, Necchi A, Loriot Y, Powles T, Plimack ER, Sonpavde G, Roupret M, Kamat AM. Role of Checkpoint Inhibition in Localized Bladder Cancer. European urology oncology. 2018 Aug;1(3):190-8.
Hahn NM, Necchi A, Loriot Y, Powles T, Plimack ER, Sonpavde G, Roupret M, Kamat AM. Role of Checkpoint Inhibition in Localized Bladder Cancer. European urology oncology. 2018 Aug;1(3):190-8.
Necchi A, Pond GR, Moschini M, Plimack ER, Niegisch G, Yu EY, Bamias A, Agarwal N, Vaishampayan U, Theodore C, Sridhar SS, Rosenberg JE, Bellmunt J, Gallina A, Colombo R, Montorsi F, Briganti A, Galsky MD. Development of a Prediction Tool for Exclusive Locoregional Recurrence After Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer. Clin Genitourin Cancer. 2018 Sep 13;.
Necchi A, Pond GR, Pal SK, Agarwal N, Bowles DW, Plimack ER, Yu EY, Ladoire S, Baniel J, Crabb S, Niegisch G, Srinivas S, Berthold DR, Rosenberg JE, Powles T, Bamias A, Harshman LC, Bellmunt J, Galsky MD, Retrospective International Study of Invasive/Advanced Cancer of the Urothelium G. Bone Metastases as the Only Metastatic Site in Patients With Urothelial Carcinoma: Focus on a Special Patient Population. Clin Genitourin Cancer. 2018 Apr;16(2):e483-e490.
Ristau BT, Smaldone MC. Performance Measurement and Quality Improvement Initiatives for Bladder Cancer Care. Current urology reports. 2018 Oct 24;19(12):100.   PMCID: Review
Tripathi A, Plimack ER. Immunotherapy for Urothelial Carcinoma: Current Evidence and Future Directions. Current urology reports. 2018 Nov 07;19(12):109.
Huo J, Chu Y, Chamie K, Smaldone MC, Boorjian SA, Baillargeon JG, Kuo YF, Kerr P, O'Malley P, Orihuela E, Tyler DS, Freedland SJ, Giordano SH, Vikram R, Kamat AM, Williams SB. Increased Utilization of Positron Emission Tomography/Computed Tomography (PET/CT) Imaging and Its Economic Impact for Patients Diagnosed With Bladder Cancer. Clin Genitourin Cancer. 2017 Jul 26;.   PMCID: PMC5878135
Ramos JD, Wingate JT, Gulati R, Plimack ER, Harshman LC, Powles T, Crabb SJ, Niegisch G, Bellmunt J, Ladoire S, De Giorgi U, Hussain S, Alva AS, Baniel J, Agarwal N, Rosenberg JE, Vaishampayan UN, Galsky MD, Yu EY. Venous Thromboembolism Risk in Patients With Locoregional Urothelial Tract Tumors. Clin Genitourin Cancer. 2017 Aug 24;.   PMCID: PMC5826750
Abbosh PH, Rosenberg JE, Plimack ER. Circulating biomarkers to guide systemic therapy for urothelial carcinoma. Urol Oncol. 2016 Nov;34(11):502-9.
Geynisman DM, Handorf E, Wong YN, Doyle J, Plimack ER, Horwitz EM, Canter DJ, Uzzo RG, Kutikov A, Smaldone MC. Advanced small cell carcinoma of the bladder: clinical characteristics, treatment patterns and outcomes in 960 patients and comparison with urothelial carcinoma. Cancer medicine. 2016 Feb;5(2):192-9.   PMCID: PMC4735777
O'Donnell PH, Alanee S, Stratton KL, Garcia-Grossman IR, Cao H, Ostrovnaya I, Plimack ER, Manschreck C, Ganshert C, Smith ND, Steinberg GD, Vijai J, Offit K, Stadler WM, Bajorin DF. Clinical Evaluation of Cisplatin Sensitivity of Germline Polymorphisms in Neoadjuvant Chemotherapy for Urothelial Cancer. Clin Genitourin Cancer. 2016 Dec;14(6):511-7.   PMCID: PMC5018246
Plimack ER, Dunbrack RL, Brennan TA, Andrake MD, Zhou Y, Serebriiskii IG, Slifker M, Alpaugh K, Dulaimi E, Palma N, Hoffman-Censits J, Bilusic M, Wong YN, Kutikov A, Viterbo R, Greenberg RE, Chen DY, Lallas CD, Trabulsi EJ, Yelensky R, McConkey DJ, Miller VA, Golemis EA, Ross EA. Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer. Eur Urol. 2016 Dec;68(6):959-67.
Zibelman M, Ramamurthy C, Plimack ER. Emerging role of immunotherapy in urothelial carcinoma-Advanced disease. Urol Oncol. 2016 Dec;34(12):538-47.
Abbosh PH, McConkey DJ, Plimack ER. Targeting Signaling Transduction Pathways in Bladder Cancer. Current oncology reports. 2015 Dec;17(12):58.
Plimack ER, Dunbrack RL, Brennan TA, Andrake MD, Zhou Y, Serebriiskii IG, Slifker M, Alpaugh K, Dulaimi E, Palma N, Hoffman-Censits J, Bilusic M, Wong YN, Kutikov A, Viterbo R, Greenberg RE, Chen DY, Lallas CD, Trabulsi EJ, Yelensky R, McConkey DJ, Miller VA, Golemis EA, Ross EA. Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer. Eur Urol. 2015 Dec;68(6):959-67.   PMCID: PMC4764095
Willis DL, Flaig TW, Hansel DE, Milowsky MI, Grubb RL, Al-Ahmadie HA, Plimack ER, Koppie TM, McConkey DJ, Dinney CP, Hoffman VA, Droller MJ, Messing E, Kamat AM. Micropapillary bladder cancer: current treatment patterns and review of the literature. Urol Oncol. 2014 Aug;32(6):826-32.   PMCID: PMC4687398
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term Bladder cancer

Bladder cancer Urothelial carcinoma Nomogram Perioperative chemotherapy Pd-1 pathology Urinary Bladder Neoplasms Immunotherapy Localized Therapy Neoadjuvant Therapy Treatment Risk prediction Fgfr3 Biomarkers Chemotherapy Cisplatin sensitivity Cisplatin resistance Neoadjuvant chemotherapy Ctla-4 Transitional Cell Carcinoma Non-muscle-invasive therapeutic use Checkpoint inhibitors Checkpoint inhibitor Immune checkpoint blockade Atm Muscle-invasive Prognosis Fancc Rb1 drug therapy Pet Relapse-free survival Sunitinib Pharmacogenomics Cystectomy Adult Treatment response prediction epidemiology Targeted therapy Middle Aged 80 and over Aged Cisplatin pd-1 Review Cell Cycle Checkpoints DNA Repair Metastatic CTLA-4 Antigen Pik3ca pd-l1 B7-H1 Antigen Neoplasm Invasiveness Pazopanib treatment patterns therapy Prospective Studies genetics Positron emission tomography-computed tomography Precision medicine ctla-4 Preclinical Drug Evaluation Erbb3 methods Micropapillary Erbb2 Bevacizumab Radiotherapy urothelial carcinoma Survey statistics & numerical data Retrospective Studies Bone metastases Copy number abnormality Urothelial cancer outcomes Protein Kinase Inhibitors Non-urothelial immunology Circulating tumor cells Performance measurement mTOR Dovitinib Adjuvant Chemotherapy PD-L1 blockade physiology Evidence-based Cetuximab Egfr Everolimus Immunological Antineoplastic Agents Aged Erlotinib DNA repair Programmed Cell Death 1 Receptor Pd-l1 Pten antagonists & inhibitors Imaging Medical Oncology Outcomes of chemotherapy Platinum ineligible small cell bladder cancer PD-1 blockade Cell-free DNA Physicians' Practice Patterns Combined Modality Therapy Oncolytic virus Male Monoclonal Antibodies Circulating tumor DNA Clinical trials Thrombosis Female Outcomes of bone-only metastatic urothelial carcinoma Outcome measurement Antineoplastic Agents Quality improvement Genetic Markers Mutation ct
Last updated on Friday, January 03, 2020